Eric Kim is currently the Director of Clinical Science at Pfizer Oncology, where they focus on the development of Sigvotatug vedotin (SGN-B6A). Previously, they served as a Principal Clinical Scientist at Seagen and Pfizer, specializing in late-stage clinical development in oncology. Eric's past experience includes roles as an Early Clinical Scientist Fellow at Merck and Adjunct Faculty at Rutgers University. They hold a Doctor of Pharmacy (PharmD), a Bachelor of Science (B.S.) in Biochemistry, and are pursuing a Master of Business Administration (MBA) in Finance at Washington State University.
This person is not in any teams
This person is not in any offices